Ductal carcinoma in situ: Biology, diagnosis, and new therapies

Clinical Breast Cancer

Volumn 7, Issue 9, 2007, Pages 16-21

  Valenzuela, Marcia ^a,b   Julian, Thomas B ^a,c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b Hospital Eduardo Pereira   (Chile)

^c NSABP Foundation Inc   (United States)

Author keywords

Biopsy; Molecular markers; Non invasive breast cancer

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CARCINOMA; CALCIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DUCTAL CARCINOMA IN SITU; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; MAMMOGRAPHY; NEEDLE BIOPSY; PARTIAL MASTECTOMY; REVIEW;

EID: 34548331577     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.026     Document Type: Review

References (62)

1. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913-918.
2. Nakhlis F, Morrow M. Ductal carcinoma in situ. Surg Clin North Am 2003; 83:821-839.
3. Bhathal PS, Brown RW, Lesueur GC, et al. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985; 51:271-278.
4. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women. Cancer 1984; 54:612-615.
5. Bartow SA, Pathak DR, Black WC, et al. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk breast to cancer: a forensic autopsy study. Cancer 1987; 60:2751-2760.
6. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985; 16:796-807.
7. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer 1980; 46(4 suppl):919-925.
8. Eusebi Y Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994; 11:223-235.
9. Collins L, Tamimi R, Baer H, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005; 103:1778-1784.
10. Leonard G, Swain S. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96:906-920.
11. Rosen PP, Oberman HA. In: Juan Rosai, ed. Atlas of Tumor Pathology, 3rd Series. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology; 1993.
12. Moriya T, Silverberg SG. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma. Cancer 1994; 74:2972-2978.
13. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66:102-108.
14. Barnes DM, Meyer JS, Gonzalez JG, et al. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res Treat 1991; 18:11-17.
15. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990; 21:1164-1167.
16. Quinn CM, Ostrowski JL, Parkin GJ, et al. Ductal carcinoma in situ of the breast: the clinical significance of histological classification. Histopathology 1997; 30:113-119.
17. Lennington WJ, Jensen RA, Dalton LW, et al. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994; 73:118-124.
18. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345:1154-1157.
19. Douglas-Jones AG, Gupta SK, Attanoos RL. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology 1996; 29:397-409.
20. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997; 80:1798-1802.
21. Miller FR, Soule HD, Tait L, et al. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 1993; 85:1725-1732.
22. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999; 187:272-278.
23. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health study. JAMA 1999; 281:2091-2097.
24. O'Connell P, Pekkel Y Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast cancer lesions at 15 genetic loci. J Natl Cancer Inst 1998; 90:697-703.
25. Zhuang Z, Merino MJ, Chuaqui R, et al. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res 1995; 55:467-471.
26. Ottesen GL, Christensen IJ, Larsen JK, et al. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res Treat 2000; 60:219-226.
27. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Related Cancer 2001; 8:47-61.
28. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in situ carcinoma of the breast analysed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994; 11:208-214.
29. Warnberg F, Nordgren H, Bergkvist L, et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001; 85:869-874.
30. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001; 28:400-418.
31. Jeffrey SS, Pollack JR. The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res 2003; 5:320-328.
32. Perou CM, Sorlie T, Elsen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
33. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100:5974-5979.
34. Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980; 192:139-147.
35. Ikeda DM. Mammographic analysis of breast calcifications. In: Ikeda D, ed. Breast Imaging. Philadelphia, PA: Elsevier Mosby; 2004.
36. Ernster V, Ballard-Barbash R, Barlow W, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94:1546-1554.
37. Hwang ES. Ductal carcinoma in situ: surgical update and future directions. ASCO 2005 Educational Book. Alexandria, VA: ASCO; 2005:80-83.
38. Liberman M, Menell J. Breast imaging reporting and data system (BI-RADS). Radiol Clin N Am 2002; 40:409-430.
39. Bassett LW Noninvasive carcinoma. In: Diagnosis of Diseases of the Breast, 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005.
40. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218:497-502.
41. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997; 202:843-847.
42. Won B, Reynolds HE, Lazaridis CL, et al. Stereotactic biopsy of ductal carcinoma in situ of the breast using an 11-gauge vacuum-assisted device: persistent underestimation of disease. Am J Roentgenol 1999; 173:227-229.
43. Meyer JE, Smith DN, Lester SC, et al. Large-core needle biopsy of nonpalpable breast lesions. JAMA 1999; 281:1638-1641.
44. Liberman L. Percutaneous image-guided core breast biopsy. Radiol Clin N Am 2002; 40:483-500.
45. Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 1995; 196:115-122.
46. Boetes C, Mus RD, Holland R, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 1995; 197:743-747.
47. Bruce D, Ikeda D. Magnetic resonance imaging of breast cancer and MRI-guided breast biopsy. In Ikeda D, ed. Breast Imaging. Philadelphia: Elsevier Mosby; 2004.
48. Menell JH, Morris EA, Dershaw DD, et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 2005; 11:382-390.
49. Gilles R, Meunier M, Lucidarme O, et al. Clustered breast microcalcifications: evaluation by dynamic contrast-enhanced subtraction MRI. J Comput Assist Tomogr 1996; 20:9-14.
50. Gilles R, Guinebretiere JM, Lucidarme O, et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 1994; 191:625-631.
51. Fisher B, Anderson S, Bryant J, et al. Twenty year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233-1241.
52. Veronesi U, Cascinelli N, Mariani L, et al. Twenty year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347:1227-1232.
53. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853- a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24:3381-3387.
54. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355:528-533.
55. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999; 86:429-438.
56. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362:95-102.
57. Faverly DR, Burgers L, Bult P, et al. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 1994; 11:193-198.
58. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993-2000.
59. Allred DC, Bryant J, Land SR, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Presented at: San Antonio Breast Cancer Symposium; December 11-14, 2002; San Antonio, TX. Abstract #30.
60. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
61. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
62. Gonzalez RJ, Buzdar AU, Fraser Symmans W, et al. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (Herceptin). Breast J 2007; 13:72-75.